Wednesday, June 9, 2010
Sunday, February 7, 2010
America developed a new tool for diagnosis and treatment of cancer
26, published a paper, said the researchers developed a gene mapping tool that can better diagnose and treatment of common tumors.
According to Agence France-Presse reported, this study focused on mapping the most common and deadly brain tumor molecular characteristics of early, resulting in nuclear magnetic resonance scanning to distinguish it belongs to what type of seeds.
The paper published in the United States, "National Academy of Sciences" magazine published an advance on. Paper the main author, University of California, San Diego, Michael? Guo (sound) said that the same method can also be used to better identify other tumor types.
Guo and his research team used samples to be tested in vivo for different sub-types of cancer genetic structure, mapping, and these results provide in vivo mapping of samples of patients with MRI scan results were compared.
He said: "This is a powerful, scalable technology. It can be with different combination of scanning technology, but also can be applied to different types of tumors, such as liver cancer."
Although this technology for clinical applications still need to undergo further tests before, but it can help doctors confirm the future, what kind of treatment for the tumor sub-types of what to design a better treatment programs.
Guo said: "The medical goal is the right medicine. This technology has the potential are showing signs that might help us achieve this goal the initial prospects."
According to Agence France-Presse reported, this study focused on mapping the most common and deadly brain tumor molecular characteristics of early, resulting in nuclear magnetic resonance scanning to distinguish it belongs to what type of seeds.
The paper published in the United States, "National Academy of Sciences" magazine published an advance on. Paper the main author, University of California, San Diego, Michael? Guo (sound) said that the same method can also be used to better identify other tumor types.
Guo and his research team used samples to be tested in vivo for different sub-types of cancer genetic structure, mapping, and these results provide in vivo mapping of samples of patients with MRI scan results were compared.
He said: "This is a powerful, scalable technology. It can be with different combination of scanning technology, but also can be applied to different types of tumors, such as liver cancer."
Although this technology for clinical applications still need to undergo further tests before, but it can help doctors confirm the future, what kind of treatment for the tumor sub-types of what to design a better treatment programs.
Guo said: "The medical goal is the right medicine. This technology has the potential are showing signs that might help us achieve this goal the initial prospects."
Friday, February 5, 2010
Peritoneal mesothelioma drug therapy
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Treatment
PMM moderately sensitive to chemotherapy drug. Preoperative induction chemotherapy, surgery and postoperative adjuvant chemotherapy could reduce tumor recurrence and improve 3-year survival rate.
PMM effects of chemical treatment of certain drugs doxorubicin, cisplatin, carboplatin, bleomycin and domestic anti-cancer drugs Eiemene so. Vincristine, fluorouracil, cyclophosphamide, mitomycin, also worth a try. Doxorubicin (Adriamycin, ADM) for each adult 30 ~ 60mg/m2, every 3 weeks a time, intravenous or intraperitoneal injection, total dose not exceed 550mg/m2. Adverse reactions to cardiac toxicity, as the, and there is accumulation of sex, and the total dose-related; followed by bone marrow suppression, gastrointestinal reactions and hair loss.
Cisplatin (Cisplatin, DDP, cis-platinum) Adult per 80 ~ 120mg/m2, every 3 weeks a time; or 20mg/m2, used in conjunction 5 days every 3 weeks for a course of treatment, intravenous injection. Adverse reactions are nephrotoxicity, ototoxicity, neurotoxicity, gastrointestinal reactions and inhibit bone marrow. Mannitol was added to reduce the accumulation in renal tubules.
Carboplatin (Carboplatin, CBP) for adults for each 300 ~ 400mg/m2, 5% glucose solution or saline, the diluted to the concentration of 0.5mg/ml solution, intravenous drip, repeated every 3 ~ 4 weeks, or 100mg / d by adding 500ml of 5% glucose solution intravenously qd for 5 days; 3 ~ 4 weeks to repeat one time. Can also be used for each intraperitoneal injection of 300 ~ 500mg per week, an times.
Bleomycin (Bleomycin, BLM) for adults 15 ~ 30mg, dissolved in an appropriate saline or 5% glucose solution in the deep intramuscular injection, intravenous injection or intravenous drip, 2 times per week; also be replaced by a second depending on the circumstances / d, or several times a week. Can also be used intraperitoneal injection of 60mg slowly dissolved. Stey intraperitoneal injection with BLM treatment of 1 case PMM patients, the results of ascites disappeared after stopping does not occur again, survive more than 3 years. However, BLM intraperitoneal injection of large doses can cause pneumonia-like symptoms, or pulmonary fibrosis; In addition, fever, gastrointestinal reactions more common, occurring allergic individual patients.
Taxol (Paclitaxel) This product is extracted from the bark of Taxus anticancer drugs, by inducing and promoting tubulin polymerization and stability to prevent depolymerization of microtubules, inhibit cell division and proliferation. Paclitaxel can inhibit mitotic microtubule network required for regeneration, prevent the formation of the mitotic spindle leading to chromosome breaks, inhibition of tumor cell replication. Dose of 135 ~ 175 mg/m2, diluted in normal saline or 5% glucose solution intravenously. Repeated every 3 weeks. 12 hours before treatment should be given dexamethasone 20 mg, 30 ~ 60 minutes ago to be intravenous diphenhydramine 50 mg and cimetidine 300 mg or ranitidine 200 mg, to prevent allergic reactions. Cis-platinum combined with about 66.7% of patients on the force and capability by its toxicity. Adverse reactions are bone marrow suppression, allergic reactions, arthralgia, myalgia, gastrointestinal reactions, peripheral neuropathy, syncope, ataxia, and injection site pain and swelling and so on.
Eiemene (Elemene) Curcuma extract of traditional Chinese medicine to the anti-cancer active substance; chest, intra-abdominal perfusion in the treatment of malignant chest, ascites has good curative effect. In as far as possible after the extraction ascites by intraperitoneal injection of 200 ~ 400mg/m2 usage, 1 ~ 2 times a week. The incidence of adverse reactions was 20% ~ 70%, mainly fever, chills and pain; such as a pre-injection of a small amount of narcotic drugs and hormones, are able to prevent them; other allergic reactions, gastrointestinal reactions.
Cyclophosphamide (CTX) for adults for each 600 ~ 1200mg, week 1 ~ 2 times, intravenous injection. After treatment of bone marrow suppression, gastrointestinal reactions and hemorrhagic adverse events than those in common bladder Yandeng.
Vincristine (VCR) for adults per 2.5 ~ 8mg/m2, week 1, intravenous injection, total volume of 60 ~ 80mg, major adverse reactions of bone marrow suppression.
Methotrexate (MTX) for adults every 15 ~ 50mg, week 1 ~ 2 times, muscle or intravenously. Side effects are bone marrow suppression, gastrointestinal reactions, stomatitis, liver and kidney dysfunction, etc., long-term medication can cause pulmonary fibrosis.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Treatment
PMM moderately sensitive to chemotherapy drug. Preoperative induction chemotherapy, surgery and postoperative adjuvant chemotherapy could reduce tumor recurrence and improve 3-year survival rate.
PMM effects of chemical treatment of certain drugs doxorubicin, cisplatin, carboplatin, bleomycin and domestic anti-cancer drugs Eiemene so. Vincristine, fluorouracil, cyclophosphamide, mitomycin, also worth a try. Doxorubicin (Adriamycin, ADM) for each adult 30 ~ 60mg/m2, every 3 weeks a time, intravenous or intraperitoneal injection, total dose not exceed 550mg/m2. Adverse reactions to cardiac toxicity, as the, and there is accumulation of sex, and the total dose-related; followed by bone marrow suppression, gastrointestinal reactions and hair loss.
Cisplatin (Cisplatin, DDP, cis-platinum) Adult per 80 ~ 120mg/m2, every 3 weeks a time; or 20mg/m2, used in conjunction 5 days every 3 weeks for a course of treatment, intravenous injection. Adverse reactions are nephrotoxicity, ototoxicity, neurotoxicity, gastrointestinal reactions and inhibit bone marrow. Mannitol was added to reduce the accumulation in renal tubules.
Carboplatin (Carboplatin, CBP) for adults for each 300 ~ 400mg/m2, 5% glucose solution or saline, the diluted to the concentration of 0.5mg/ml solution, intravenous drip, repeated every 3 ~ 4 weeks, or 100mg / d by adding 500ml of 5% glucose solution intravenously qd for 5 days; 3 ~ 4 weeks to repeat one time. Can also be used for each intraperitoneal injection of 300 ~ 500mg per week, an times.
Bleomycin (Bleomycin, BLM) for adults 15 ~ 30mg, dissolved in an appropriate saline or 5% glucose solution in the deep intramuscular injection, intravenous injection or intravenous drip, 2 times per week; also be replaced by a second depending on the circumstances / d, or several times a week. Can also be used intraperitoneal injection of 60mg slowly dissolved. Stey intraperitoneal injection with BLM treatment of 1 case PMM patients, the results of ascites disappeared after stopping does not occur again, survive more than 3 years. However, BLM intraperitoneal injection of large doses can cause pneumonia-like symptoms, or pulmonary fibrosis; In addition, fever, gastrointestinal reactions more common, occurring allergic individual patients.
Taxol (Paclitaxel) This product is extracted from the bark of Taxus anticancer drugs, by inducing and promoting tubulin polymerization and stability to prevent depolymerization of microtubules, inhibit cell division and proliferation. Paclitaxel can inhibit mitotic microtubule network required for regeneration, prevent the formation of the mitotic spindle leading to chromosome breaks, inhibition of tumor cell replication. Dose of 135 ~ 175 mg/m2, diluted in normal saline or 5% glucose solution intravenously. Repeated every 3 weeks. 12 hours before treatment should be given dexamethasone 20 mg, 30 ~ 60 minutes ago to be intravenous diphenhydramine 50 mg and cimetidine 300 mg or ranitidine 200 mg, to prevent allergic reactions. Cis-platinum combined with about 66.7% of patients on the force and capability by its toxicity. Adverse reactions are bone marrow suppression, allergic reactions, arthralgia, myalgia, gastrointestinal reactions, peripheral neuropathy, syncope, ataxia, and injection site pain and swelling and so on.
Eiemene (Elemene) Curcuma extract of traditional Chinese medicine to the anti-cancer active substance; chest, intra-abdominal perfusion in the treatment of malignant chest, ascites has good curative effect. In as far as possible after the extraction ascites by intraperitoneal injection of 200 ~ 400mg/m2 usage, 1 ~ 2 times a week. The incidence of adverse reactions was 20% ~ 70%, mainly fever, chills and pain; such as a pre-injection of a small amount of narcotic drugs and hormones, are able to prevent them; other allergic reactions, gastrointestinal reactions.
Cyclophosphamide (CTX) for adults for each 600 ~ 1200mg, week 1 ~ 2 times, intravenous injection. After treatment of bone marrow suppression, gastrointestinal reactions and hemorrhagic adverse events than those in common bladder Yandeng.
Vincristine (VCR) for adults per 2.5 ~ 8mg/m2, week 1, intravenous injection, total volume of 60 ~ 80mg, major adverse reactions of bone marrow suppression.
Methotrexate (MTX) for adults every 15 ~ 50mg, week 1 ~ 2 times, muscle or intravenously. Side effects are bone marrow suppression, gastrointestinal reactions, stomatitis, liver and kidney dysfunction, etc., long-term medication can cause pulmonary fibrosis.
Monday, February 1, 2010
Peritoneal mesothelioma chemotherapy
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Chemotherapy:
To give a systemic anti-cancer chemotherapy drug, the peritoneal cavity less drug distribution. Foreign reports, whether single-agent or combination therapy, systemic chemotherapy, efficiency is only 11% ~ 14%. Combination chemotherapy programs include: DDP + ADM, DDP + CTX + VCR, CTX + VCR + BLM and so on. But many scholars stressed that the chemotherapy does not improve the curative effect. Poulain, etc. In vitro studies of the DDP, CBP and amphotericin B (AmB) in malignant mesothelioma cell lines in cytotoxicity. Cell line exposure to these drugs two hours, six days later --- inhibit the growth curve shows that the concentration of 5 ~ 10mg / L of AmB on sensitive or resistant cell lines to DDP, and CBP can be 50% of growth - inhibitory concentration (IC50) reduced by 5 ~ 10 times. The role of AmB may be associated with a significant increase in the tumor cells to platinum intake, increased intracellular concentration of platinum, platinum enhanced cytotoxic effects. Phosphodiesterase inhibition methylxanthine (phosphodiesterase inhibiting methylxanthines) and AmB had synergistic effect, its own toxicity is weak, and can alleviate the toxicity of AmB kidney. But so far no clinical report of the joint application of these drugs.
2 intraperitoneal chemotherapy in recent years that the intraperitoneal injection drug use can increase local drug concentrations, reducing systemic adverse reactions; not only the eradication of residual tumor tissue after surgery to reduce the recurrence; also allows partial loss surgery patients the opportunity to reduce the mass, ascites reduced, disease has been effectively controlled.
Intra-abdominal and intravenous dose once a dosage similar to or slightly higher than the latter; 1 week later to repeat. According to the disease can be a continuous injection for several weeks. Ito and so can not give one cases of surgical resection of patients with PMM intraperitoneal injection DDP, and the combination of uracil and tegafur, made an unexpected effect: In the 223 days after abdominal mass and ascites disappeared completely. But in the first 8 months after the recurrence of pelvic masses; re-awarded to DDP and camptothecin, the effect is poor. Ma, etc. are heated by continuous hyperthermic peritoneal perfusion (continuous hyperthermic peritoneal perfusion, CHPP) combined local injection of DDP treatment of PPM. The average amount of the initial DDP infusion 120mg/ml (81 ~ 166mg/ml), perfusion flow rate 1.5L/min, the average infusion volume of 5.1L (4 ~ 7L), reperfusion after 90 minutes, measuring intra-abdominal temperature were three 41.5 ℃, 40.5 ℃ and 41.1 ℃. DDP infusion fluid total area under the curve (AUC) for plasma DDP AUC 21-fold, plasma concentrations and systemic DDP when medication is similar. Course of treatment, no significant local adverse reactions, patients are able to tolerate CHPP. Follow-up of 10 months, no one cases of death due to CHPP treatment. Park, also has similar coverage. It seems now, CHPP as good for the treatment of PMM is an effective way.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Chemotherapy:
To give a systemic anti-cancer chemotherapy drug, the peritoneal cavity less drug distribution. Foreign reports, whether single-agent or combination therapy, systemic chemotherapy, efficiency is only 11% ~ 14%. Combination chemotherapy programs include: DDP + ADM, DDP + CTX + VCR, CTX + VCR + BLM and so on. But many scholars stressed that the chemotherapy does not improve the curative effect. Poulain, etc. In vitro studies of the DDP, CBP and amphotericin B (AmB) in malignant mesothelioma cell lines in cytotoxicity. Cell line exposure to these drugs two hours, six days later --- inhibit the growth curve shows that the concentration of 5 ~ 10mg / L of AmB on sensitive or resistant cell lines to DDP, and CBP can be 50% of growth - inhibitory concentration (IC50) reduced by 5 ~ 10 times. The role of AmB may be associated with a significant increase in the tumor cells to platinum intake, increased intracellular concentration of platinum, platinum enhanced cytotoxic effects. Phosphodiesterase inhibition methylxanthine (phosphodiesterase inhibiting methylxanthines) and AmB had synergistic effect, its own toxicity is weak, and can alleviate the toxicity of AmB kidney. But so far no clinical report of the joint application of these drugs.
2 intraperitoneal chemotherapy in recent years that the intraperitoneal injection drug use can increase local drug concentrations, reducing systemic adverse reactions; not only the eradication of residual tumor tissue after surgery to reduce the recurrence; also allows partial loss surgery patients the opportunity to reduce the mass, ascites reduced, disease has been effectively controlled.
Intra-abdominal and intravenous dose once a dosage similar to or slightly higher than the latter; 1 week later to repeat. According to the disease can be a continuous injection for several weeks. Ito and so can not give one cases of surgical resection of patients with PMM intraperitoneal injection DDP, and the combination of uracil and tegafur, made an unexpected effect: In the 223 days after abdominal mass and ascites disappeared completely. But in the first 8 months after the recurrence of pelvic masses; re-awarded to DDP and camptothecin, the effect is poor. Ma, etc. are heated by continuous hyperthermic peritoneal perfusion (continuous hyperthermic peritoneal perfusion, CHPP) combined local injection of DDP treatment of PPM. The average amount of the initial DDP infusion 120mg/ml (81 ~ 166mg/ml), perfusion flow rate 1.5L/min, the average infusion volume of 5.1L (4 ~ 7L), reperfusion after 90 minutes, measuring intra-abdominal temperature were three 41.5 ℃, 40.5 ℃ and 41.1 ℃. DDP infusion fluid total area under the curve (AUC) for plasma DDP AUC 21-fold, plasma concentrations and systemic DDP when medication is similar. Course of treatment, no significant local adverse reactions, patients are able to tolerate CHPP. Follow-up of 10 months, no one cases of death due to CHPP treatment. Park, also has similar coverage. It seems now, CHPP as good for the treatment of PMM is an effective way.
Wednesday, January 27, 2010
Biochemical treatment of peritoneal mesothelioma
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Biological response modifier therapy:
Biological response modifiers (biological response modifier, BRM) some of the body's own cells and molecules, can answer to stimulate the body's internal and external environment, and to participate in the body to maintain environmental stability. BRM through the mobilization of the inherent capacity of the body to resist and eliminate cancer, become the new mode of treatment of cancer. With the cell engineering and genetic engineering progress, BRM come in handy in the field of cancer therapy.
Cytokines: interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), etc. In addition to direct anti-tumor cells, and can be activated in vivo anti-cancer cells, or secretion of anti-cancer effects of molecules, or maintain the immune response cell proliferation and differentiation features, PMM can be used as adjuvant therapy.
Adoptive transfer of immune cells: collection, separation of malignant ascites in the lymphocytes, in vitro expansion, and induces cytotoxicity issued Lymphokine Activated Killer cells (LAK cells) and integrate it into the body, there are anti-tumor cells. At the same time to give IL-2, can improve efficacy. Tani and so will the patient's own lymphocytes and malignant mesothelioma cells in mixed culture, to be anti-monoclonal antibody and IL-2 activation of the generated cytotoxic T cells (CTL). Activated CTL against malignant mesothelioma cells have a high degree of self-cytotoxicity. PMM to the two cases reported in the literature, while patients with chemotherapy, intra-abdominal injection of CTL as an auxiliary therapy, the results of ascites subsided gradually disappeared tumor blocks, improving the patient's quality of life.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Biological response modifier therapy:
Biological response modifiers (biological response modifier, BRM) some of the body's own cells and molecules, can answer to stimulate the body's internal and external environment, and to participate in the body to maintain environmental stability. BRM through the mobilization of the inherent capacity of the body to resist and eliminate cancer, become the new mode of treatment of cancer. With the cell engineering and genetic engineering progress, BRM come in handy in the field of cancer therapy.
Cytokines: interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), etc. In addition to direct anti-tumor cells, and can be activated in vivo anti-cancer cells, or secretion of anti-cancer effects of molecules, or maintain the immune response cell proliferation and differentiation features, PMM can be used as adjuvant therapy.
Adoptive transfer of immune cells: collection, separation of malignant ascites in the lymphocytes, in vitro expansion, and induces cytotoxicity issued Lymphokine Activated Killer cells (LAK cells) and integrate it into the body, there are anti-tumor cells. At the same time to give IL-2, can improve efficacy. Tani and so will the patient's own lymphocytes and malignant mesothelioma cells in mixed culture, to be anti-monoclonal antibody and IL-2 activation of the generated cytotoxic T cells (CTL). Activated CTL against malignant mesothelioma cells have a high degree of self-cytotoxicity. PMM to the two cases reported in the literature, while patients with chemotherapy, intra-abdominal injection of CTL as an auxiliary therapy, the results of ascites subsided gradually disappeared tumor blocks, improving the patient's quality of life.
Monday, January 25, 2010
Related to the treatment of peritoneal mesothelioma
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
PMM for the rare peritoneal malignancy, has always held that the prognosis is poor, so far there is no standardized treatment protocols, but this situation is expected to change. In recent years, based on surgery, chemotherapy, radiotherapy, immune therapy has been supplemented by a combination therapy began to take shape.
On the chief complaint of chronic abdominal pain, abdominal distention, the elderly patients, especially those with ascites, and (or) abdominal mass who, by ultrasound or CT examination confirmed the intra-abdominal mass or peritoneal nodules on; ascites was exudative ascites and transparent quality acid was significantly higher; serum CA125 increase should be highly suspected PMM. For these patients should be ultrasound or CT guided biopsy, laparoscopy, or laparotomy; in estimating the range of tumor spread, while visceral and parietal peritoneum in multiple biopsy to obtain adequate organization for pathological examination and organization of the immune or chemical examination. Most patients diagnosed PMM, has been difficult to completely remove the tumor surgery. If no obstruction performance, should provide 2 to 3 treatment-induced intra-abdominal chemotherapy, in order to minimize the surface of tumor growing in the intestine, in order to create the conditions for surgery and help clinicians master the tumor response to chemotherapy information. After induction chemotherapy in 2 months, the purposes of cytoreductive surgery, removal of peritoneal disease, so as to remove all tumor tissue. Intraoperative or early postoperative intraperitoneal should be given adjuvant chemotherapy, and adjuvant treatment with radiotherapy and BRM. On postoperative tumor recurrence, such as conditions permit, consideration should be given re-operation.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
PMM for the rare peritoneal malignancy, has always held that the prognosis is poor, so far there is no standardized treatment protocols, but this situation is expected to change. In recent years, based on surgery, chemotherapy, radiotherapy, immune therapy has been supplemented by a combination therapy began to take shape.
On the chief complaint of chronic abdominal pain, abdominal distention, the elderly patients, especially those with ascites, and (or) abdominal mass who, by ultrasound or CT examination confirmed the intra-abdominal mass or peritoneal nodules on; ascites was exudative ascites and transparent quality acid was significantly higher; serum CA125 increase should be highly suspected PMM. For these patients should be ultrasound or CT guided biopsy, laparoscopy, or laparotomy; in estimating the range of tumor spread, while visceral and parietal peritoneum in multiple biopsy to obtain adequate organization for pathological examination and organization of the immune or chemical examination. Most patients diagnosed PMM, has been difficult to completely remove the tumor surgery. If no obstruction performance, should provide 2 to 3 treatment-induced intra-abdominal chemotherapy, in order to minimize the surface of tumor growing in the intestine, in order to create the conditions for surgery and help clinicians master the tumor response to chemotherapy information. After induction chemotherapy in 2 months, the purposes of cytoreductive surgery, removal of peritoneal disease, so as to remove all tumor tissue. Intraoperative or early postoperative intraperitoneal should be given adjuvant chemotherapy, and adjuvant treatment with radiotherapy and BRM. On postoperative tumor recurrence, such as conditions permit, consideration should be given re-operation.
Wednesday, January 20, 2010
The anti-liver cancer drug --- Raspberry
Raspberries are rich in a large number of "Tanning acid" that can inhibit tumor growth. In addition, grapes, apples and other fruits are also inhibit tumor cell proliferation.
Beauty beauty of fruit can be added vitamins, but the 4th Hospital of Harbin Medical University experts found that its more important role: the prevention of primary liver cancer. Recently, Jin was admitted four hospital Dr. Liu Ming, vice president of applications, "the National Natural Science Foundation of China Project" has been approved, Dr. Liu Ming of the fruit began formal study of the role of liver cancer. The near future, prone to liver cancer in high-risk groups will be able to enjoy the results of this study.
Jin was admitted four homes, according to Dr. Liu Ming, vice president of introduction, raspberry-rich large number of "Tanning acid" that can inhibit tumor growth. In addition, grapes, apples and other fruits are also inhibit tumor cell proliferation. At present, Liu has established a raspberry prevention of primary liver cancer study group, and from Shangzhi purchased a large quantity of raspberry repeated studies. If successful, they can take advantage of raspberry extract in the production of pharmaceutical preparations or oral, for the use of high-risk groups susceptible to liver cancer. Liu said that the liver is called the "cancer of the King", once contracted, is very small chance of cure. Hepatitis B virus carriers, rural long-term consumption of moldy grain populations, and have a family genetic history of the long-term consumption of high-risk groups if raspberry, grape and other fruits, can effectively prevent primary liver cancer.
On how a reasonable intake of fruits, Liu made the following three proposals: First, at least a day eating grapes, apples, oranges, etc., or two or more fruit, if and cauliflower, tomatoes, carrots and other vegetables with consumption of three or more, the effect is more good; Second, grapes, apples and other fruits soaked, cleaned, it is best consumed as a whole, not peeled; three daily intake of vegetables and fruits, not less than 400-500 grams, and the fruits, vegetables, varieties should be diverse .
Beauty beauty of fruit can be added vitamins, but the 4th Hospital of Harbin Medical University experts found that its more important role: the prevention of primary liver cancer. Recently, Jin was admitted four hospital Dr. Liu Ming, vice president of applications, "the National Natural Science Foundation of China Project" has been approved, Dr. Liu Ming of the fruit began formal study of the role of liver cancer. The near future, prone to liver cancer in high-risk groups will be able to enjoy the results of this study.
Jin was admitted four homes, according to Dr. Liu Ming, vice president of introduction, raspberry-rich large number of "Tanning acid" that can inhibit tumor growth. In addition, grapes, apples and other fruits are also inhibit tumor cell proliferation. At present, Liu has established a raspberry prevention of primary liver cancer study group, and from Shangzhi purchased a large quantity of raspberry repeated studies. If successful, they can take advantage of raspberry extract in the production of pharmaceutical preparations or oral, for the use of high-risk groups susceptible to liver cancer. Liu said that the liver is called the "cancer of the King", once contracted, is very small chance of cure. Hepatitis B virus carriers, rural long-term consumption of moldy grain populations, and have a family genetic history of the long-term consumption of high-risk groups if raspberry, grape and other fruits, can effectively prevent primary liver cancer.
On how a reasonable intake of fruits, Liu made the following three proposals: First, at least a day eating grapes, apples, oranges, etc., or two or more fruit, if and cauliflower, tomatoes, carrots and other vegetables with consumption of three or more, the effect is more good; Second, grapes, apples and other fruits soaked, cleaned, it is best consumed as a whole, not peeled; three daily intake of vegetables and fruits, not less than 400-500 grams, and the fruits, vegetables, varieties should be diverse .
Subscribe to:
Posts (Atom)